Detalhe da pesquisa
1.
Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
Virol J
; 21(1): 79, 2024 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38570803
2.
The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
Liver Int
; 38(6): 1064-1073, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29164767
3.
Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy.
J Gastroenterol Hepatol
; 33(10): 1766-1772, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29514418
4.
Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
J Formos Med Assoc
; 117(11): 1011-1018, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29254684
5.
Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease.
J Formos Med Assoc
; 117(4): 268-275, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28947134
6.
Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study.
J Formos Med Assoc
; 117(9): 833-840, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29089161
7.
The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice.
J Formos Med Assoc
; 116(11): 852-861, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28888355
8.
Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy.
J Antimicrob Chemother
; 71(7): 1943-7, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27073265
9.
Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
J Gastroenterol Hepatol
; 31(7): 1307-14, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26758501
10.
A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
Clin Gastroenterol Hepatol
; 13(5): 1017-24, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25460552
11.
The validation of the 2010 American Association for the Study of Liver Diseases guideline for the diagnosis of hepatocellular carcinoma in an endemic area.
J Gastroenterol Hepatol
; 30(2): 345-51, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25092265
12.
Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation.
J Hepatol
; 60(6): 1127-34, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24583247
13.
Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections.
Arch Virol
; 159(1): 29-37, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23857507
14.
Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis.
J Gastroenterol Hepatol
; 29(3): 568-75, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24716215
15.
Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community.
Am J Gastroenterol
; 108(3): 416-24, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23318478
16.
Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Am J Kidney Dis
; 62(4): 789-95, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23746377
17.
Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessation.
J Infect Public Health
; 16(11): 1852-1859, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37837921
18.
Inhibition of lncRNA RPPH1 activity decreases tumor proliferation and metastasis through down-regulation of inflammation-related oncogenes.
Am J Transl Res
; 15(12): 6701-6717, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38186977
19.
A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
J Antimicrob Chemother
; 67(3): 696-9, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22174039
20.
A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy.
J Antimicrob Chemother
; 67(11): 2766-72, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22899800